Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanoma
Various immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade
Updates in CINV Including NCCN Guideline Revisions
In our last issue, we published a review of treatment options for acute and delayed chemotherapy-induced nausea and vomiting. Since then, a few things have happened on this front.
Sam Donaldson Hosts Roundtable on End-of-Life Care for Cancer Patients
The National Comprehensive Cancer Network (NCCN) 15th Annual Meeting in March opened with a roundtable discussion on "Cancer Care at the End of Life: When is Enough Enough?"
Clinical and Economic Considerations for the Use of Erythropoiesis-Stimulating Agents
Erythropoiesis-stimulating agents (ESAs) are genetically engineered forms of erythropoietin that stimulate erythropoiesis through direct or indirect action on the erythropoietin receptor producing an increase
Challenges in Treating Chemotherapy-Induced Anemia
Practicing clinicians and healthcare administrators face many challenges in treating cancer patients, including management of chemotherapy-induced anemia.
Biology and Management of Diffuse Large B-cell Lymphoma
Recent statistics show lymphoid malignancies to be the fifth most common cause of cancer-related death in the United States.
Moving Beyond Standard of Care: Novel Treatments in Gynecologic Cancer
In the United States, gynecologic cancers affect nearly 80,000 women annually and are the cause of death in more than 25,000 women.
Kareem Abdul-Jabbar Takes on a Tough Opponent:Chronic Myeloid Leukemia
Author of six bestselling books, a television and film actor, and a filmmaker; Abdul-Jabbar is gaining fame for a role he never wanted: that of a chronic myeloid leukemia (CML) patient.
Judge Rules Myriad Cannot Patent BRCA1 and BRCA2-Genes
A US district court invalidated 7 of 23 of Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes, which confer an increased risk of developing breast, ovarian, and prostate cancers.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512